Leap Therapeutics and BeiGene are announcing the exclusive option and license agreement for DKN-01 and Leap.

Leap Therapeutics and BeiGene are announcing the exclusive option and license agreement for DKN-01 and Leap.

Leap Therapeutics, Inc., a biotechnology company developing selective immuno-oncology medication, and BeiGene, Ltd., a commercial-stage biopharmaceutical company focusing on the development and marketing of novel molecular and immuno-oncology medicines for cancer treatment, today announced an exclusive right and licensing arrangement…